Beyond Resectability: Molecular Selection for Salvage Surgery after Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Non-Small Cell Lung Cancer
Journal of Chest Surgery · 05.11.2026 · 59 (6) · 304-305
DOI: 10.5090/jcs.26.115 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Chest Surgery, online erschienen am 12.08.2026. Verfasst von Zurui Liu. Beteiligte Einrichtung: Department of Thoracic Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Thoracic Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
ORCID-Profile: Zurui Liu
Zitieren
APA
Liu, Z. (2026). Beyond Resectability: Molecular Selection for Salvage Surgery after Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Non-Small Cell Lung Cancer. Journal of Chest Surgery, 59(6), 304-305. https://doi.org/10.5090/jcs.26.115
Vancouver
Liu Z. Beyond Resectability: Molecular Selection for Salvage Surgery after Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Non-Small Cell Lung Cancer. Journal of Chest Surgery. 2026;59(6):304-305. doi:10.5090/jcs.26.115
BibTeX
@article{Liu2026,
author = {Liu, Zurui},
title = {Beyond Resectability: Molecular Selection for Salvage Surgery after Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Non-Small Cell Lung Cancer},
journal = {Journal of Chest Surgery},
year = {2026},
volume = {59},
number = {6},
pages = {304--305},
doi = {10.5090/jcs.26.115}
}
EUVIMED